GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oruka Therapeutics Inc (FRA:HQ1) » Definitions » Dividend Yield %

Oruka Therapeutics (FRA:HQ1) Dividend Yield % : 0.00% (As of Apr. 09, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Oruka Therapeutics Dividend Yield %?

As of today (2025-04-09), the Trailing Annual Dividend Yield of Oruka Therapeutics is 0.00%.

The historical rank and industry rank for Oruka Therapeutics's Dividend Yield % or its related term are showing as below:

FRA:HQ1's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.57
* Ranked among companies with meaningful Dividend Yield % only.

Oruka Therapeutics's Dividend Payout Ratio for the six months ended in Dec. 2024 was 0.00.

As of today (2025-04-09), the Forward Dividend Yield % of Oruka Therapeutics is 0.00%.

Oruka Therapeutics's Dividends per Share for the six months ended in Dec. 2024 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


Oruka Therapeutics Dividend Yield % Historical Data

The historical data trend for Oruka Therapeutics's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oruka Therapeutics Dividend Yield % Chart

Oruka Therapeutics Annual Data
Trend Dec24
Dividend Yield %
-

Oruka Therapeutics Semi-Annual Data
Dec24
Dividend Yield % -

Competitive Comparison of Oruka Therapeutics's Dividend Yield %

For the Biotechnology subindustry, Oruka Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oruka Therapeutics's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oruka Therapeutics's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Oruka Therapeutics's Dividend Yield % falls into.


;
;

Oruka Therapeutics Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Oruka Therapeutics  (FRA:HQ1) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Oruka Therapeutics Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Oruka Therapeutics's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Oruka Therapeutics Business Description

Traded in Other Exchanges
Address
855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Oruka Therapeutics Headlines

No Headlines